Antipsychotic‐Induced Hyperprolactinemia
dc.contributor.author | Bostwick, Jolene R. | en_US |
dc.contributor.author | Guthrie, Sally K. | en_US |
dc.contributor.author | Ellingrod, Vicki L. | en_US |
dc.date.accessioned | 2012-03-16T15:57:29Z | |
dc.date.available | 2012-03-16T15:57:29Z | |
dc.date.issued | 2009-01 | en_US |
dc.identifier.citation | Bostwick, Jolene R.; Guthrie, Sally K.; Ellingrod, Vicki L. (2009). "Antipsychotic‐Induced Hyperprolactinemia." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29(1). <http://hdl.handle.net/2027.42/90238> | en_US |
dc.identifier.issn | 0277-0008 | en_US |
dc.identifier.issn | 1875-9114 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/90238 | |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.subject.other | Sexual Dysfunction | en_US |
dc.subject.other | Hyperprolactinemia | en_US |
dc.subject.other | Prolactin | en_US |
dc.subject.other | Antipsychotics | en_US |
dc.subject.other | Schizophrenia | en_US |
dc.subject.other | Osteoporosis | en_US |
dc.subject.other | Breast Cancer | en_US |
dc.subject.other | Amenorrhea | en_US |
dc.title | Antipsychotic‐Induced Hyperprolactinemia | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan (all authors). | en_US |
dc.identifier.pmid | 19113797 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/90238/1/phco.29.1.64.pdf | |
dc.identifier.doi | 10.1592/phco.29.1.64 | en_US |
dc.identifier.source | Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | en_US |
dc.identifier.citedreference | Meaney, A.M., Smith, S., Howes, O.D., O'Brien, M., Murray, R.M., O'Keane, V.. Effects of long‐term prolactin‐raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004; 184: 503 – 8. | en_US |
dc.identifier.citedreference | Thangavelu, K., Geetanjali, S.. Menstrual disturbance and galactorrhea in people taking conventional antipsychotic medications. Exper Clin Psychopharmacol 2006; 14: 459 – 60. | en_US |
dc.identifier.citedreference | Lambert, M., Haro, J.M., Novick, D. et al. Olanzapine vs. other antipsychotics in actual out‐patient settings: six months tolerability results from the European schizophrenia out‐patient health outcomes study. Acta Psychiatr Scand 2005; 111: 232 – 43. | en_US |
dc.identifier.citedreference | Bobes, J., García‐Portilla, M.P., Rejas, J. et al. Frequency of sexual dysfunction and other reproductive side‐effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003; 29: 125 – 47. | en_US |
dc.identifier.citedreference | Kelly, D.L., Conley, R.R.. Sexuality and schizophrenia: a review. Schizophr Bull 2004; 30: 767 – 79. | en_US |
dc.identifier.citedreference | Knegtering, H., van der Moolen, A.E., Castelein, S., Kluiter, H., van den Bosch, R.J.. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?. Psychoneuro-endocrinology 2003; 28 ( suppl 2 ): 109 – 23. | en_US |
dc.identifier.citedreference | Riecher‐Rossler, A.. Oestrogens and schizophrenia. Curr Opin Psychiatry 2003; 16: 187 – 92. | en_US |
dc.identifier.citedreference | Huber, T.J., Rollnik, J., Wilhelms, J., von zur Mühlen, A., Emrich, H.M., Schneider, U.. Estradiol levels in psychotic disorders. Psychoneuroendocrinology 2001; 26; 27 – 35. | en_US |
dc.identifier.citedreference | Liu‐Seifert, H., Kinon, B.J., Ahl, J., Lamberson, S.. Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin‐elevating antipsychotics. Ann N Y Acad Sci 2004; 1032: 297 – 8. | en_US |
dc.identifier.citedreference | Howard, L., Kirkwood, G., Leese, M.. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007; 190: 129 – 34. | en_US |
dc.identifier.citedreference | Hankinson, S.E., Willett, W.C., Michaud, D.S. et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999; 91: 629 – 34. | en_US |
dc.identifier.citedreference | Tworoger, S.S., Hankinson, S.E.. Prolactin and breast cancer risk. Cancer Lett 2006; 243: 160 – 9. | en_US |
dc.identifier.citedreference | Wang, P.S., Walker, A.M., Tsuang, M.T. et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002; 59: 1147 – 54. | en_US |
dc.identifier.citedreference | Halbreich, U., Shen, J., Panaro, V.. Are chronic psychiatric patients at increased risk for developing breast cancer?. Am J Psychiatry 1996; 153: 559 – 60. | en_US |
dc.identifier.citedreference | Szarfman, A., Tonning, J.M., Levine, J.G., Doraiswamy, P.M.. Atypical antipsychotics and pituitary tumors: a pharmaco‐vigilance study. Pharmacotherapy 2006; 26: 748 – 58. | en_US |
dc.identifier.citedreference | Marder, S.R., Essock, S.M., Miller, A.L. et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334 – 49. | en_US |
dc.identifier.citedreference | Wolf, J., Fiedler, U.. Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. J Clin Pharm Ther 2007; 32: 197 – 8. | en_US |
dc.identifier.citedreference | Shim, J.C., Shin, J.G., Kelly, D.L. et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic‐induced hyperprolactinemia: a placebo‐controlled trial. Am J Psychiatry 2007; 164: 1404 – 10. | en_US |
dc.identifier.citedreference | Bankowski, B.J., Zacur, H.A.. Dopamine agonist therapy for hyperprolactinemia. Clin Obstet Gynecol 2003; 46: 349 – 62. | en_US |
dc.identifier.citedreference | Naidoo, U., Goff, D.C., Klibanski, A.. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003; 28: 97 – 108. | en_US |
dc.identifier.citedreference | Perkins, D.O.. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63: 1121 – 8. | en_US |
dc.identifier.citedreference | Fleischhacker, W.W., Meise, U., Gunther, V., Kurz, M.. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatrica Scand 1994; 89 ( suppl 382 ): 11 – 15. | en_US |
dc.identifier.citedreference | Halbreich, U.. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation. CNS Drugs 2007; 21: 641 – 57. | en_US |
dc.identifier.citedreference | Misra, M., Papakostas, G.I., Klibanski, A.. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004; 65: 1607 – 18. | en_US |
dc.identifier.citedreference | Lehman, D., Meyer, J.M.. Decreased bone mineral density in male schizophrenia patients. Schizophr Res 2005; 76: 131 – 3. | en_US |
dc.identifier.citedreference | Haddad, P.M., Wieck, A.. Antipsychotic‐induced hyper‐prolactinemia: mechanisms, clinical features, and management. Drugs 2004; 64: 2291 – 314. | en_US |
dc.identifier.citedreference | Ben‐Jonathan, N., Hugo, E.R., Brandebourg, T.D., LaPensee, C.R.. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006; 17: 110 – 16. | en_US |
dc.identifier.citedreference | Harris, J., Stanford, P.M., Oakes, S.R., Ormandy, C.J.. Prolactin and prolactin receptor: new targets of an old hormone. Ann Med 2004; 36: 414 – 25. | en_US |
dc.identifier.citedreference | Parker, K.L., Schimmer, B.P.. Pituitary hormones and their hypothalamic releasing hormones. In: Brunton, L.L., Lazo, J.S., Parker, K.L., eds. Goodman & Gilman's the pharmacologic basis of therapeutics, 11th ed. New York: McGraw‐Hill Companies, Inc., 2006: 1489 – 510. | en_US |
dc.identifier.citedreference | Young, R.M., Lawford, B.R., Barnes, M. et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry 2004; 185: 147 – 51. | en_US |
dc.identifier.citedreference | Thompson, J., Thomas, N., Singleton, A. et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7: 479 – 84. | en_US |
dc.identifier.citedreference | Nordström, A.L., Farde, L.. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug‐treated patients. J Clin Psychopharmacol 1998; 18: 305 – 10. | en_US |
dc.identifier.citedreference | Mihara, K., Kondo, T., Suzuki, A. et al. Prolactin response to nemonapride, a selective antagonist for D2, like dopamine receptors, in schizophrenic patients in relation to Taq 1 A polymorphism of DRD2 gene. Psychopharmacology 2000; 149: 246 – 50. | en_US |
dc.identifier.citedreference | Molitch, M.E.. Medication‐induced hyperprolactinemia. Mayo Clin Proc 2005; 80: 1050 – 7. | en_US |
dc.identifier.citedreference | Melmed, S., Jameson, J.L.. Disorders of the anterior pituitary and hypothalamus. In: Kasper, D.L., Fauci, A.S., Longo, D.L., Braunwald, E., Hauser, S.L., Jameson, J.L., eds. Harrison's principles of internal medicine, 16th ed. New York: McGraw‐Hill Companies, Inc., 2005: 2076 – 97. | en_US |
dc.identifier.citedreference | Byerly, M., Suppes, T., Tran, Q., Baker, R.A.. Clinical implications of antipsychotic‐induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007; 27: 639 – 61. | en_US |
dc.identifier.citedreference | Kinon, B.J., Gilmore, J.A., Liu, H., Halbreich, U.M.. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003; 28: 55 – 68. | en_US |
dc.identifier.citedreference | Maguire, G.A.. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002; 63 ( suppl 4 ): 56 – 62. | en_US |
dc.identifier.citedreference | Crismon, M.L., Buckley, P.F.. Schizophrenia. In: DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M., eds. Pharmacotherapy a pathophysiologic approach, 6th ed. New York: McGraw‐Hill Companies, Inc., 2005; 1209 – 33. | en_US |
dc.identifier.citedreference | Halbreich, U., Kinon, B.J., Gilmore, J.A., Kahn, L.S.. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse events. Psychoneuroendocrinology 2003; 28: 53 – 67. | en_US |
dc.identifier.citedreference | Meyer, J.M., Lehman, D.. Bone mineral density in male schizophrenia patients: a review. Ann Clin Psychiatry 2006; 18: 43 – 8. | en_US |
dc.identifier.citedreference | Hummer, M., Malik, P., Gasser, R.W. et al. Osteoporosis in patients with schizophrenia. Am J Psychiatry 2005; 162: 162 – 7. | en_US |
dc.identifier.citedreference | Meaney, A.M., O'Keane, V.. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res 2007; 93: 136 – 43. | en_US |
dc.identifier.citedreference | Welsch, C.W., Nagasawa, H.. Prolactin and murine mammary tumorigenesis: a review. Cancer Res 1977; 37: 951 – 63. | en_US |
dc.identifier.citedreference | Palmer, J., Maurer, L.H.. Prolactin and breast cancer [letter]. Lancet 1972; 2: 1036. | en_US |
dc.identifier.citedreference | Minton, J.P.. Prolactin and human breast cancer. Am J Surg 1974; 128: 628 – 30. | en_US |
dc.identifier.citedreference | Janssen Pharmaceutica Products, L.P.. Risperdal (risperidone) package insert. Titusville, NJ; 2007. | en_US |
dc.identifier.citedreference | Knegtering, R., Baselmans, P., Castelein, S., Bosker, F., Bruggeman, R., van den Bosch, R.J.. Predominate role of the 9‐hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005; 162: 1010 – 12. | en_US |
dc.identifier.citedreference | Rosenheck, R.A., Leslie, D.L., Sindelar, J., et al. Cost‐effectiveness of second‐generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163: 2080 – 9. | en_US |
dc.identifier.citedreference | Kuruvilla, A., Peedicayil, J., Srikrishna, G., Kuruvilla, K., Kanagasabapathy, A.S.. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharm Physiol 1992; 19: 603 – 6. | en_US |
dc.identifier.citedreference | Smith, S., Wheeler, M.J., Murray, R., O'Keane, V.. The effects of antipsychotic‐induced hyperprolactinaemia on the hypothalamic‐pituitary‐gonadal axis. J Clin Psychopharmacol 2002; 22: 109 – 14. | en_US |
dc.identifier.citedreference | Kim, K.S., Pae, C.U., Chae, J.H. et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002; 63: 408 – 13. | en_US |
dc.identifier.citedreference | Kane, J., Canas, F., Kramer, M. et al. Treatment of schizophrenia with paliperidone extended‐release tablets: a 6‐week placebo‐controlled trial. Schizophr Res 2007; 90: 147 – 61. | en_US |
dc.identifier.citedreference | Crawford, A.M.K., Beasley, C.M., Tollefson, G.D.. The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997; 26: 41 – 54. | en_US |
dc.identifier.citedreference | Bergemann, N., Mundt, C., Parzer, P. et al. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res 2005; 73: 357 – 66. | en_US |
dc.identifier.citedreference | Weiden, P.J., Daniel, D.G., Simpson, G., Romano, S.J.. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003; 23: 595 – 600. | en_US |
dc.identifier.citedreference | Arvanitis, L.A., Miller BG, for the Seroquel Trial 13 Study Group. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233 – 46. | en_US |
dc.identifier.citedreference | Kane, J.M., Carson, W.H., Saha, A.R. et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763 – 71. | en_US |
dc.identifier.citedreference | Haddad, P.M., Sharma, S.G.. Adverse effects of atypical antipsychotics differential risk and clinical implications. CNS Drugs 2007; 21: 911 – 36. | en_US |
dc.identifier.citedreference | Zito, J.M., Safer, D.J., dosReis, S. et al. Psychotropic practice patterns for youth: a 10‐year perspective. Arch Pediatr Adolesc Med 2003; 157: 17 – 25. | en_US |
dc.identifier.citedreference | Zito, J.M., Safer, D.J., Valluri, S., Gardner, J.F., Korelitz, J.J., Mattison, D.R.. Psychotherapeutic medication prevalence in Medicaid‐insured preschoolers. J Child Adolesc Psychopharmacol 2007; 17: 195 – 203. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.